These mechanistic insights suggest that the CD68/CD163 ratio could serve as a clinically meaningful biomarker for thrombotic risk stratification, potentially guiding prophylactic anticoagulation strategies in high-risk MPN patients. This evidence concerns the gene CD163 and myeloproliferative neoplasm.